Elevance Adds Former Cencora CEO Steve Collis to Board Amid Pharmacy Services Growth

Elevance Health has named Steve Collis, former CEO of Cencora, to its board of directors. Collis has three decades of experience in the drug distribution industry and will serve on Elevance's audit and finance committees. His expertise is expected to be valuable for Elevance's Carelon health services division, which includes pharmacy benefits manager CarelonRx. The division's revenue was up 20% in Q2, while operating profit rose 8%. Elevance plans to continue investing in growth.

Elevance Health (NYSE: ELV) has announced the addition of Steve Collis to its board of directors, effective August 1. Collis, a seasoned global healthcare executive, brings three decades of experience in the drug distribution industry. He will serve on the Audit and Finance Committees, enhancing Elevance's financial oversight capabilities [1].

Collis is currently the Executive Chairman of Cencora (formerly AmerisourceBergen), where he has held several key executive leadership positions. Notably, he served as President and CEO from 2011 to 2024, leading significant strategic transformations. His appointment to Elevance Health reflects the company's commitment to board evolution and sound governance [1].

Elevance Health's Carelon health services division, which includes pharmacy benefits manager CarelonRx, is expected to benefit from Collis's expertise. The division's revenue grew by 20% in Q2 2025, while operating profit rose by 8%. Elevance plans to continue investing in growth [1].

Ramey Peru, Chair of the Elevance Health Board of Directors, stated, "Steve brings a distinguished record of leadership, transformation, and operational excellence. His insights will support our continued focus on delivering high-quality care, driving innovation, and creating enduring value for the people and communities we serve" [1].

References:
[1] https://www.elevancehealth.com/newsroom/elevance-health-board-welcomes-steve-collis-as-new-director